LEXIE KOBER: Open Payments
NPI 1508476383 · LAKE CHARLES, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,804 in 101 payments from 26 companies in 2025. Trend: 2023 $93 · 2024 $790 · 2025 $1,804
Food & beverage: $1,804
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $298 |
| Lilly USA, LLC | 9 | $152 |
| AstraZeneca Pharmaceuticals LP | 6 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $131 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $109 |
| Novo Nordisk Inc | 6 | $103 |
| Sumitomo Pharma America, Inc. | 4 | $99 |
| Otsuka America Pharmaceutical, Inc. | 4 | $88 |
| Amgen Inc. | 3 | $61 |
| Phathom Pharmaceuticals, Inc. | 5 | $60 |
Products named: BREZTRI, TRINTELLIX, VRAYLAR, CAPLYTA, MOUNJARO, UBRELVY, GEMTESA, REXULTI.
Industry payments across LA — which companies pay providers there.
